Serum matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in esophageal cancer patients

Folia Histochemica et Cytobiologica

Volumn 50, Issue 4, 2012, Pages 590-598

  Groblewska, Magdalena ^a   Mroczko, Barbara ^a   Kozlowski, Miroslaw ^a   Niklinski, Jacek ^a   Laudanski, Jerzy ^a   Szmitkowski, Maciej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

CEA; Esophageal cancer; Matrix metalloproteinase 2; SCC; Survival; Tissue inhibitor of matrix metalloproteinases 2; Tumor marker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ANTIGEN DETECTION; AREA UNDER THE CURVE; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ESOPHAGUS CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

EID: 84871759106     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2012.0083     Document Type: Article

References (34)

1. Crew KD, Neugut A. Epidemiology of upper gastrointestinal malignancies. Semin Oncol. 2004;31:450-464.
2. Pohn H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142-146.
3. Parkin MD, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
4. Blot WJ, McLaughlin JK, Fraumeni JF Jr. Esophageal cancer. In: Schottenfeld D, Fraumeni JF Jr., ed. Cancer Epidemiology and Prevention. New York: Oxford University Press; 2006:697-706.
5. El-Shahat M, Lotfy M, Fahmy L et al. Prognostic value of microvessel density, matrix metalloproteinase-9 and p53 protein expression in esophageal cancer. J Egypt Natl Cancer Inst. 2004;16:224-230.
6. Vallbohmer D, Lenz HJ. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus. 2006;19:425-432.
7. Samantaray S, Sharma R, Chattopadhyaya TK et al. Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2004;130:37-44.
8. Gu ZD, Li JY, Li M et al. Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. Am J Gastroenterol. 2005;100:1835-1843.
9. Sato H, Kida Y, Mai M et al. Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene. 1992;7:77-83.
10. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer. 2002;99:157-166.
11. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer. 2003;89:1270-1275.
12. Kubben FJ, Sier CF, Meijer MJ et al. Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer. 2006;95:744-751.
13. Giannopoulos G, Pavlakis K, Parasi A et al. The expression of matrix metalloproteinases-2 and-9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters. Anticancer Res. 2008;28:1875-1881.
14. Murnane MJ, Cai J, Shuja S, McAneny D, Klepeis V, Willett JB. Active MMP-2 effectively identifies the presence of colorectal cancer. Int J Cancer. 2009;125:2893-2902.
15. Li Y, Ma J, Guo Q et al. Overexpression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. Dis Esophagus. 2009;22:664-667.
16. Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res. 2004;64:7622-7628.
17. Sharma R, Chattopadhyay TK, Mathur M, Ralhan R. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer. Oncology. 2004;3-4:300-309.
18. Chen YK, Chang WS, Wu IC et al. Molecular characterization of invasive subpopulations from an esophageal squamous cell carcinoma cell line. Anticancer Res. 2010;3:727-736.
19. Chen W, Abnet CC, Wei WQ et al. Serum markers as predictors of esophageal squamous dysplasia and early cancer. Anticancer Res. 2004;24:3245-3249.
20. Sobin LH, Wittenkind C. International Union Against Cancer (UICC) TNM classification of malignant tumours, 5th edition. New York: Willey-Liss;1997.
21. Mroczko B, Kozłowski M, Groblewska M et al. The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients. Clin Chim Acta. 2008;389:61-66.
22. Newcombe RG. Two-sided confidence intervals for the single proportion: Comparison of seven methods. Stat Med. 1998;17:857-872.
23. Brockmann JG, St Nottberg H, Glodny B, Heinecke A, Senninger NJ. CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res. 2000;6:4249-4252.
24. Shimada H, Nabeya Y, Tagawa M et al. Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci. 2003;94:628-632.
25. Groblewska M, Mroczko B, Gryko M, Ke{ogonek}dra B, Szmitkowski M. Matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in the diagnosis of colorectal adenoma and cancer patients. Folia Histochem Cytobiol. 2010;48:564-571.
26. Mroczko B, Lukaszewicz-Zaja{ogonek}c M, Gryko M, Ke{ogonek}dra B, Szmitkowski M. Clinical significance of serum levels of matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor (TIMP-2) in gastric cancer. Folia Histochem Cytobiol. 2011;49:125-131.
27. Waas E, Wobbes T, Ruers T, Lomme R, Hendriks T. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease. Eur J Surg Oncol. 2006;32:756-763
28. Oberg A, Höyhtyä M, Tavelin B, Stenling R, Lindmark G. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res. 2000;20:1085-1091.
29. Waas E, Hendriks T, Lomme R, Wobbes T. Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum. 2005;48:700-710.
30. Fujimoto N, Mouri N, Iwata K, Ohuchi E, Okada Y, Hayakawa T. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. Clin Chim Acta 1993;221:91-103.
31. Endo K, Maehara Y, Baba H et al. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res. 1997;17:2253-2258.
32. Pozzi A, LeVine WF, Gardner HA. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 2002;21:272-81.
33. Łukaszewicz-Zaja{ogonek}c M, Mroczko B, Kozłowski M, Nikliński J, Laudański J, Szmitkowski M. Clinical significance of serum macrophage-colony stimulating factor (M-CSF) in esophageal cancer patients and its comparison with classical tumor markers. Clin. Chem. Lab. Med. 2010;48:1467-1473.
34. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J. Pathol. 1998;185:256-261.